Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Other(2)

Detailed Status

unknown2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

unknown2100%

Recent Activity

0 active trials
Showing 2 of 2
unknownphase_1

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

NCT05514158
unknownphase_1

A Study of RC98 in Subjects With Advanced Malignant Solid Tumors

NCT04190823

Clinical Trials (2)

Showing 2 of 2 trials
NCT05514158Phase 1

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Unknown
NCT04190823Phase 1

A Study of RC98 in Subjects With Advanced Malignant Solid Tumors

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2